These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 27467139)

  • 1. Safety and efficacy considerations due to misuse of extended-release formulations of stimulant medications.
    Jain R; Stark JG
    Postgrad Med; 2016 Sep; 128(7):672-81. PubMed ID: 27467139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential for misuse and abuse of medications in ADHD: a review.
    Clemow DB; Walker DJ
    Postgrad Med; 2014 Sep; 126(5):64-81. PubMed ID: 25295651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abuse of medications employed for the treatment of ADHD: results from a large-scale community survey.
    Bright GM
    Medscape J Med; 2008 May; 10(5):111. PubMed ID: 18596945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on the pharmacokinetic considerations in the treatment of ADHD with long-acting methylphenidate and amphetamine formulations.
    Childress AC; Komolova M; Sallee FR
    Expert Opin Drug Metab Toxicol; 2019 Nov; 15(11):937-974. PubMed ID: 31581854
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion.
    Faraone SV; Wilens TE
    J Clin Psychiatry; 2007; 68 Suppl 11():15-22. PubMed ID: 18307377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature.
    Wilens TE; Adler LA; Adams J; Sgambati S; Rotrosen J; Sawtelle R; Utzinger L; Fusillo S
    J Am Acad Child Adolesc Psychiatry; 2008 Jan; 47(1):21-31. PubMed ID: 18174822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances and considerations in attention-deficit/hyperactivity disorder pharmacotherapy.
    Mohammadi M; Akhondzadeh S
    Acta Med Iran; 2011; 49(8):487-98. PubMed ID: 22009816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Misuse of Methylphenidate.
    Clemow DB
    Curr Top Behav Neurosci; 2017; 34():99-124. PubMed ID: 26695166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
    Najib J
    Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
    Gibson AP; Bettinger TL; Patel NC; Crismon ML
    Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety.
    Heal DJ; Cheetham SC; Smith SL
    Neuropharmacology; 2009 Dec; 57(7-8):608-18. PubMed ID: 19761781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on the clinical pharmacology of methylphenidate: therapeutic efficacy, abuse potential and future considerations.
    Shellenberg TP; Stoops WW; Lile JA; Rush CR
    Expert Rev Clin Pharmacol; 2020 Aug; 13(8):825-833. PubMed ID: 32715789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder.
    Upadhyaya HP
    J Clin Psychiatry; 2007; 68 Suppl 11():23-30. PubMed ID: 18307378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The science of stimulant abuse.
    Greenhill LL
    Pediatr Ann; 2006 Aug; 35(8):552-6. PubMed ID: 16986449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety of extended-release drug formulations for the treatment of ADHD.
    Childress A
    Expert Opin Drug Saf; 2017 May; 16(5):603-615. PubMed ID: 28393639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADHD medication use, adherence, persistence and cost among Texas Medicaid children.
    Barner JC; Khoza S; Oladapo A
    Curr Med Res Opin; 2011; 27 Suppl 2():13-22. PubMed ID: 21973228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of effect of oral long-acting stimulant medications for ADHD throughout the day.
    Brams M; Moon E; Pucci M; López FA
    Curr Med Res Opin; 2010 Aug; 26(8):1809-25. PubMed ID: 20491612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.